HP HALDEN PHARMA AS

Operating

Produksjon og salg av legemidler, parenteral og medisinsk infusjons- og ernæringsterapi og lignende produkter og relatert virksomhet, samt å yte konsulenttjenester, forvaltning av egne eiendeler og erverv og forvaltning av aksjeposter i selskaper innen helse og farmasøytisk virksomhet.

Produksjon av legemidler, å tilby konsulenttjenester, forvaltning av egne eiendeler, og erverv og forvaltning av aksjeposter i selskaper innen farmasøyt- og helsesektoren.

Keywords

productionpharmaceuticalsantiserablood fractionsvaccineshomeopathic preparationscontraceptive productsbone buildingdiagnostic preparationspregnancy testsbiotechnological medicinescotton woolgasbandagesdressings

Organization

CEO: SM
Sebastian Marcus Heckerodt1979
Chairman of the board: OP
Otto Prange1951
Years since formation: 3 years; since Apr 20, 2023
Type: Limited company
VAT registered: Yes
Number of employees: 692

Ownership

Number of shares and share classes: 10,000,000; 1 share class
Total number of shareholders: 1; person

Financials

Total operating income 2025: 1,679,892,716; NOK
Annual total result 2025: 99,702,463; NOK
Total equity 2025: 185,105,821; NOK

Last update: Aug 12, 2026

Management

Management / administration

Name	Role	Shares
SM Sebastian Marcus Heckerodt 1979	Managing Director/CEO	-

Board

Name	Role	Shares
OP Otto Prange 1951	Chairman	-
DR Dietmar Rohleder 1966	Board Member	-
TJ Tone Janikke Gummesen Thon 1973	Board Member	-
TA Tore Andreas Brevig 1981	Board Member	-
SC Siw-Hege Christiansen 1986	Board Member	-
FR Frank Roger Los 1980	Alternate Member	-
VM Veslemøy Minge Engh 1994	Alternate Member	-
CL Christine Louise Thorvik Østensvig 1994	Alternate Member	-
AA Amru Al Hashimi 1989	Alternate Member	-
VR Vibeke Røstengen-Selldin 1971	Alternate Member	-
BF Bettina Fuderholz 1973	Board Member	-
AS Anja Semmler 1969	Board Member	-

Others

Name	Role	Shares
A AS REVISION	Auditor	-

Last update: Mar 15, 2025

Ownership

Company shareholders

Name	Share class	Total number of shares	Share
PG Pharma Gmbh Prange	Ordinary shares	10,000,000	100 %

Last update: Jun 2, 2025

Financials

in NOK

Summary

Year	2025	2024	2023
Total operating income	1,679,892,716	1,262,240,824	0
Annual Total Result	99,702,463	47,832,633	0
Total assets	968,015,459	815,206,030	10,118,657
Total liabilities	782,909,637	757,373,396	118,657
Total equity	185,105,821	57,832,634	10,000,000

P&L

Year	2025	2024
Total operating income	1,679,892,716	1,262,240,824
Total operating costs	1,535,520,705	1,185,933,939
Operating result	144,372,011	76,306,885
Financial income/costs	-16,485,491	-14,926,758
Profit before tax	127,886,520	61,380,127
Total tax & extraordinary income/cost	28,184,057	13,547,494
Annual Total Result	99,702,463	47,832,633

Balance overview

Year	2025	2024	2023
Total fixed assets	128,905,204	57,644,512	0
Total current assets	839,110,255	757,561,517	10,118,657
Total assets	968,015,459	815,206,030	10,118,657
Short term debt	323,943,005	384,606,731	118,657
Long term debt	458,966,633	372,766,665	0
Total liabilities	782,909,637	757,373,396	118,657
Contributed capital	61,171,688	10,000,000	10,000,000
Retained earnings	123,934,133	47,832,634	0
Total equity	185,105,821	57,832,634	10,000,000
Total equity and liabilities	968,015,459	815,206,030	10,118,657

Classification

21st company classification

BETA

Small company

HP HALDEN PHARMA AS931 241 818